Publications
663 results found
Tokaca N, Cui W, Faull I, et al., 2020, Clinical utility of circulating tumour (ct) DNA next generation sequencing (NGS) for target identification in diagnostic and acquired resistance settings in metastatic NSCLC (mNSCLC): Single centre experience, ANNALS OF ONCOLOGY, Vol: 31, Pages: S867-S868, ISSN: 0923-7534
Middleton G, Brock K, Savage J, et al., 2020, Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial, LANCET RESPIRATORY MEDICINE, Vol: 8, Pages: 895-904, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 88
Cui W, Yousaf N, Bhosle J, et al., 2020, Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience, ANNALS OF ONCOLOGY, Vol: 31, Pages: S1020-S1021, ISSN: 0923-7534
Peters S, Pujol J-L, Dafni U, et al., 2020, Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial, ANNALS OF ONCOLOGY, Vol: 31, Pages: S1211-S1211, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 11
Mazieres J, Tomasini P, Lusque A, et al., 2020, Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC), ANNALS OF ONCOLOGY, Vol: 31, Pages: S826-S827, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 6
Popat S, Kim HR, Ahn M-J, et al., 2020, Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial, ANNALS OF ONCOLOGY, Vol: 31, Pages: S840-S841, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 2
Popat S, Brustugun T, Cadranel J, et al., 2020, Real-world treatment outcomes with brigatinib in patients with pretreated ALK plus metastatic non-small cell lung cancer (mNSCLC), ANNALS OF ONCOLOGY, Vol: 31, Pages: S866-S866, ISSN: 0923-7534
Garcia Campelo MR, Zhu Y, Lin HM, et al., 2020, Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L, ANNALS OF ONCOLOGY, Vol: 31, Pages: S844-S844, ISSN: 0923-7534
Cortellini A, Dingemans A-MC, Arrieta O, et al., 2020, Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies., Annual Meeting of the American-Association-for-Cancer-Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 3
Evison M, Edwards J, McDonald F, et al., 2020, Stage III non-small cell lung cancer: a UK national survey of practice, Clinical Oncology, Vol: 32, Pages: 527-536, ISSN: 0936-6555
AimsThe optimal management of stage III non-small cell lung cancer (NSCLC) is widely debated and is a rapidly evolving area. However, less than one in five stage III patients in England receive optimal multimodality treatment. The aim of this study was to map commonalities and differences in clinician judgement as well as infrastructure and resources for managing stage III NSCLC.Materials and methodsWe carried out a national survey of practice in stage III NSCLC management in the UK using a 30-min web-based survey. Invitations were sent via e-mail to the British Thoracic Oncology Group and the Society of Cardiothoracic Surgery membership and a healthcare professional market research panel.ResultsIn total, 160 respondents completed the survey. Although opinion was variable, there was a preference for surgery and adjuvant chemotherapy in stage III N2 (single station) NSCLC that could be treated with lobectomy, but this preference switched to chemoradiotherapy in single-station N2 requiring a pneumonectomy or multi-station N2. The PD-L1 status influenced the treatment decision in ‘potentially resectable’ N2 for a number of clinicians who opted for concurrent chemoradiotherapy with adjuvant durvalumab when PD-L1 ≥ 1%. A joint clinic with surgeons and oncologists was considered the most important factor for shared decision making with patients. There are barriers to recommending trimodality treatment, e.g. concerns over the negative impact on quality of life. A proportion of clinicians favoured palliative treatment in certain clinical scenarios, including supraclavicular fossa lymph node metastases, patients with borderline fitness or high PD-L1 expressors >50%.DiscussionThis survey has highlighted the need for infrastructure development, such as reflex PD-L1 testing and joint surgical and oncology clinics. Further research into the impact of multimodality treatment on quality of life and education to improve confidence in multimodality treatment could
Coleman N, Yousaf N, Arkenau H-T, et al., 2020, Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in <i>ROS1</i>-Positive NSCLC, JOURNAL OF THORACIC ONCOLOGY, Vol: 15, Pages: E142-E144, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 4
Middleton G, Fletcher P, Popat S, et al., 2020, The National Lung Matrix Trial of personalized therapy in lung cancer, NATURE, Vol: 583, Pages: 807-812, ISSN: 0028-0836
- Author Web Link
- Cite
- Citations: 71
Remon J, Passiglia F, Ahn M-J, et al., 2020, Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations, JOURNAL OF THORACIC ONCOLOGY, Vol: 15, Pages: 914-947, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 89
Popat S, Grohe C, Corral J, et al., 2020, Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?, LUNG CANCER, Vol: 144, Pages: 76-84, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 26
Zauderer MG, Szlosarek PW, Le Moulec S, et al., 2020, Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 15
Camidge DR, Niu H, Kim HR, et al., 2020, Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 16
Besse B, Felip E, Clifford C, et al., 2020, AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion plus advanced/metastatic non-small cell lung cancer (NSCLC)., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 8
Borghaei H, Besse B, Bardia A, et al., 2020, Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 10
Molina-Vila M-A, Stahel RA, Dafni U, et al., 2020, Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial, 43rd ESMO Congress (ESMO), Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, Pages: 416-425, ISSN: 0022-5193
Litchfield K, Stanislaw S, Spain L, et al., 2020, Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue, CELL REPORTS, Vol: 31, ISSN: 2211-1247
- Author Web Link
- Cite
- Citations: 33
Yang JC-H, Schuler M, Popat S, et al., 2020, Afatinib for the Treatment of NSCLC Harboring Uncommon <i>EGFR</i> Mutations: A Database of 693 Cases, JOURNAL OF THORACIC ONCOLOGY, Vol: 15, Pages: 803-815, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 149
Coakley M, Popat S, 2020, Management of lung cancer, Medicine (United Kingdom), Vol: 48, Pages: 273-278, ISSN: 1357-3039
Lung cancer is a heterogeneous group of diseases at both the histopathological and molecular levels. Individual treatment plans should be based on the histological and molecular characteristics of the tumour, as well as stage of disease at diagnosis, performance status and co-morbidities. Surgery, radiotherapy, drugs including chemotherapy, targeted agents and immunotherapy, alongside expert palliative care, all have a role in the management of patients with lung cancer, depending on stage. The most recent advances include the now standard use of immunotherapy in advanced and locally advanced disease, and the increased use of stereotactic body radiotherapy. Management decisions should be made at multidisciplinary team meetings with core members including a respiratory physician, medical and clinical oncologists, thoracic surgeon, radiologist, pathologist and palliative care team member.
Minchom A, Yuan W, Crespo M, et al., 2020, Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab., Journal for ImmunoTherapy of Cancer, Vol: 8, ISSN: 2051-1426
BACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion. Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had missense mutation in BTN2A1. CONCLUSION: This case supports rechallenge of programme death receptor 1 inhibitor in cases of previous CPI sensitivity and gives molecular insights.
Felip E, Ardizzoni A, Ciuleanu T, et al., 2020, CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations, EUROPEAN JOURNAL OF CANCER, Vol: 127, Pages: 160-172, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 94
Zhang YZ, Brambilla C, Molyneaux PL, et al., 2020, Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting, The American Journal of Surgical Pathology, Vol: 44, Pages: 347-356, ISSN: 0147-5185
Nuclear grading systems for epithelioid malignant pleural mesothelioma (MPM) have been proposed but it remains uncertain if they could be applied in a biopsy-heavy setting. Using the proposed system, we conducted an independent, external validation study using 563 consecutive cases of epithelioid MPM diagnosed at our institution between 2003 and 2017, of which 87% of patients underwent biopsies only. The median number of sites sampled was 1, with a median maximum tissue dimension of 17 mm (biopsy) and 150 mm (resection). The median overall survival (OS) was 14.7 months. The frequencies of grade I, II, and III tumors were 31% (132/563), 52% (292/563), and 17% (94/563). Grade I tumors were associated with the most favorable median OS (24.7 mo) followed by grades II (12.7 mo) and III (7.2 mo). The 2-tier nuclear grade separated tumors into low grade (19.3 mo) and high grade (8.9 mo). In multivariate analysis, 3-tier nuclear grade, 2-tier nuclear grade, and mitosis-necrosis score predicted OS independent of age, procedural type, solid-predominant growth pattern, necrosis, and atypical mitosis (all P<0.001 except 2-tier nuclear grade, P=0.001). In the scenario of a single- site biopsy with tissue dimension ≤10 mm, none but age (P=0.002) were independently predictive. Our data also suggested sampling 3 sites or a maximum tissue dimension of at least 20 mm from a single site is optimal for nuclear grade assessment. In conclusion our study confirmed the utility of nuclear grade in epithelioid MPM using a biopsy-heavy cohort provided the tissue sample met minimum dimensional criteria.
Hochmair MJ, Camidge DR, Kim HR, et al., 2020, First-Line Therapy Using Brigatinib vs. Crizotinib in PatientsWith Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial, Publisher: GEORG THIEME VERLAG KG, Pages: S131-S131, ISSN: 0934-8387
Kaiser MF, Croft J, Shah P, et al., 2020, Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment, British Journal of Haematology, Vol: 189, Pages: E1-E3, ISSN: 0007-1048
Griesinger F, Camidge DR, Kim HR, et al., 2020, Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC, Publisher: KARGER, Pages: 232-232, ISSN: 2296-5270
- Author Web Link
- Cite
- Citations: 1
Lim KHJ, Popat S, 2020, Highlights in lung cancer in 2019., ESMO Open, Vol: 5, Pages: 1-1, ISSN: 2059-7029
There have been significant advances in the treatment landscape of lung cancer in the recent few years. In this podcast, Jonathan Lim (a member of the European Society for Medical Oncology Young Oncologists Committee) interviews Professor Sanjay Popat (Professor of Thoracic Medical Oncology at The Royal Marsden Hospital, UK) on the highlights of lung cancer in 2019.Professor Popat provides his perspective and contextualises how some of the key studies reported this year (including CheckMate 227, IMpower110, KEYNOTE 042, FLAURA and CASPIAN) have been practice-changing. We also discuss the current utility and caveats of PD-L1(programmed death-ligand 1) as a biomarker for immunotherapy with anti-PD1, and explore progress made in the clinical translation of circulating tumour DNA, circulating tumour cell and tumour mutational burden. Finally, we talk about the recent hype on targeting KRAS in non-small cell lung cancer, and highlight what is on the horizon in 2020. Click here to listen to the Podcast (https://soundcloud.com/bmjpodcasts/highlights-in-lung-cancer-2019?in=bmjpodcasts/sets/esmo-open).
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.